首页> 外文期刊>BMC Infectious Diseases >The impact of trimethoprim-sulfamethoxazole as Pneumocystis jiroveci pneumonia prophylaxis on the occurrence of asymptomatic bacteriuria and urinary tract infections among renal allograft recipients: a retrospective before-after study
【24h】

The impact of trimethoprim-sulfamethoxazole as Pneumocystis jiroveci pneumonia prophylaxis on the occurrence of asymptomatic bacteriuria and urinary tract infections among renal allograft recipients: a retrospective before-after study

机译:Trimethechokim-磺胺甲氧唑的影响是肾同种异体移植受者无症状细菌和泌尿道感染发生的肺细胞jiroveci肺炎:在研究前进行回顾

获取原文
           

摘要

Background The international guidelines recommend the administration of trimethoprim-sulfamethoxazole (TMP-SMX) as Pneumocystis jiroveci pneumonia (PJP) prophylaxis for six months after transplantation. The aim of this study is to evaluate the influence of TMP-SMX prophylaxis on the occurrence of asymptomatic bacteriuria (ASB) and urinary tract infections (UTIs) as cystitis and allograft pyelonephritis (AGPN) and its impact on the antimicrobial resistance pattern of causative microorganisms. Methods We have conducted a retrospective before-after study in adult renal allograft recipients with one year follow-up after transplantation. We compared the (“after”) group that received TMP-SMX as PJP prophylaxis to the (“before”) group that did not receive it. Results In total, 343 renal allograft recipients were analysed, of whom 212 (61.8?%) received TMP-SMX as PJP prophylaxis. In this study, 63 (18.4?%) did only develop ASB without UTI, 26 (7.6?%) developed cystitis and 43 (12.5?%) developed AGPN. The remaining 211 (61.5?%) renal allograft recipients did not develop any bacteriuria at all. Multivariable Cox proportional regression analysis indicated that TMP-SMX as PJP prophylaxis was not associated with reduced prevalence of ASB (Hazard ratio (HR)?=?1.52, 95?% CI?=?0.79–2.94, p =?0.213), nor with reduced incidence of cystitis (HR?=?2.21, 95?% CI?=?0.76–6.39, p =?0.144), nor AGPN (HR?=?1.12, 95?% CI?=?0.57–2.21, p =?0.751). Among the group receiving TMP-SMX as PJP prophylaxis there was a trend was observed in increase of both amoxicillin (86?% versus 70?%) and TMP-SMX (89?% versus 48?%) resistance which already appeared within the first 30?days after TMP-SMX exposure. Conclusions Among renal allograft recipients, administration of TMP-SMX as PJP prophylaxis does not prevent ASB nor UTI, however it is associated with tendency towards increased amoxicillin and TMP-SMX resistance.
机译:背景技术国际指南建议在移植后六个月施用Trimechokim-磺胺嘧嘧啶(TMP-SMX)作为肺膜肠道肺炎(PJP)预防。本研究的目的是评估TMP-SMX预防的影响对无症状菌(ASB)和尿路感染(UTI)作为膀胱炎和同种异体移植性肾盂肾炎(AGPN)的影响及其对致病微生物抗微生物抗性模式的影响。方法在成人肾同种异体移植受者的前后研究之前进行了回顾性,移植后随访一年。我们将收到TMP-SMX的(“之后”)与PJP预防的(“之前”)组进行比较,该组(“之前”)组没有收到。结果总共分析了343例肾同种异体移植受体,其中212(61.8〜%)接受TMP-SMX作为PJP预防。在这项研究中,63(18.4倍)仅在没有UTI的情况下开发ASB,26(7.6?%)发育的膀胱炎和43(12.5?%)开发AGPN。剩下的211(61.5?%)肾同种异体移植受者根本没有发展任何细菌。多变量的Cox比例回归分析表明,作为PJP预防的TMP-SMX与ASB的普及率降低(危险比(HR)?=α1.1.52,95?%CI?= 0.79-2.94,P =?0.213),也不是降低膀胱炎的发病率降低(HR?=Δ2.21,95?%CI?=?0.76-6.39,P = 0.144),也不是AGPN(HR?=?1.12,95?%CI?=?0.57-2.21,P = 0.751)。在接受TMP-SMX的基团中,作为PJP预防,在逐渐出现在第一个内已经出现的抗性(86〜70〜70倍)和TMP-SMX(89〜%与48倍)的抗性,观察到趋势。已经出现在第一个内30?TMP-SMX暴露后的天数。结论肾同种异体移植受者,TMP-SMX的施用作为PJP预防,不能预防ASB和UTI,然而它与增加的阿莫西林和TMP-SMX抗性的趋势有关。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号